A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL

Condition:   Primary Central Nervous System Lymphoma Interventions:   Drug: Orelabrutinib;   Drug: Rituximab;   Drug: Methotrexate (MTX);   Drug: Dexamethasone Sponsor:   Huashan Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials